Prolia enters range of health insurance benefits based on excellent bone density improvement
‘Prolia(generic name: denosumab),’ an Amgen Korea’s first biological osteoporosis treatment, has been registered in the health insurance benefit list since the 1st of October.
Prolia, the first and only osteoporosis treatment targeting RANKL, is a once-6-month hypodermic injection. After launche...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.